Adaptive Biotechnologies(US:ADPT)2026-02-05 22:32Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $71.7 million, representing a 63% year-over-year increase, while full-year revenue was $277 million, reflecting a 55% growth compared to the previous year [20][21] - Adjusted EBITDA for Q4 was $4.1 million, a significant improvement from a loss of $16.4 million in the same quarter last year, and for the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024 [21][22] - The net loss for Q4 was $13.6 million, and for the full year, it was $59.5 million [22] Business Line Data and Key Metrics Changes - In the MRD business, full-year revenue grew 46% year-over-year, with clinical testing revenue increasing 64% for the full year and 59% in Q4 [5][8] - clonoSEQ test volume reached 30,038 tests in Q4, up 43% year-over-year, with blood-based testing accounting for 47% of tests, an increase from 41% a year ago [8][9] - Immune medicine revenue was $9.8 million in Q4, up from $3.8 million a year ago, primarily driven by data licensing agreements with Pfizer [23] Market Data and Key Metrics Changes - The MRD pharma business saw a revenue growth of 20% year-over-year, with multiple myeloma accounting for roughly 70% of sequencing revenue [12] - The average ASP in the U.S. for clonoSEQ tests was $1,307, up 17% year-over-year, and the company expects to reach an average of $1,400 per test in 2026 [10][11] Company Strategy and Development Direction - The company aims to continue driving top-line growth while expanding margins, focusing on MRD revenue growth and profitability [14][27] - In immune medicine, the strategy includes advancing TCR antigen datasets and AI/ML modeling work, with a target net cash burn of $15-$20 million [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong sequential growth in Q1 2026 despite potential weather-related impacts on sample arrival [32] - The company anticipates clonoSEQ test volumes to grow by more than 30% year-over-year in 2026, supported by a shift towards blood-based testing and deeper community penetration [15][16] Other Important Information - The company ended the year with a strong cash balance of $227 million, excluding cash held by digital biotechnologies [24] - The MRD business is expected to generate between $255-$265 million in revenue for 2026, with a focus on maintaining disciplined spending and achieving positive adjusted EBITDA [25][26] Q&A Session Summary Question: Discussion on clonoSEQ volume trends and seasonality - Management noted that Q4 results indicate strong growth and that Q1 typically experiences some seasonality due to holidays and weather, but they remain confident in their guidance for the year [30][32] Question: Penetration rates in DLBCL and competition - Management highlighted that while DLBCL penetration is currently low, they are focusing on data generation, guideline advancements, and deepening pharma relationships to drive growth [34][36] Question: Competitor's flow cytometry assay and pricing - Management emphasized that their clonoSEQ assay is more sensitive than competitors' offerings, which positions them favorably in the market [41][43] Question: ASP pacing and payer negotiations - Management indicated that ASP growth is expected to be linear, with ongoing negotiations with key payers that could impact overall pricing [44][60] Question: EBITDA guidance for 2026 - Management clarified that they expect to achieve positive adjusted EBITDA by the end of Q4 2026, with MRD business already positive [48][49] Question: Community and blood-based testing growth assumptions - Management expressed confidence in the potential for further growth in both community and blood-based testing, with ongoing investments to drive these areas [50][52] Question: Monetization of immune medicine data - Management discussed the potential for additional data licensing deals and the value of their proprietary dataset in immunology applications [74][75]